Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women
Background: The therapeutic targeting of PD-1/PD-L1 has shown clinical efficacy in treating metastatic breast cancer. We investigated the clinical significance of measuring serum PD-L1 levels in African-American and Hispanic women with breast cancer. Methods: PD-L1 levels were measured with the ELIS...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/2/283 |
| _version_ | 1797493060132667392 |
|---|---|
| author | Yanyuan Wu Pranabananda Dutta Sheilah Clayton Amaya McCloud Jaydutt V. Vadgama |
| author_facet | Yanyuan Wu Pranabananda Dutta Sheilah Clayton Amaya McCloud Jaydutt V. Vadgama |
| author_sort | Yanyuan Wu |
| collection | DOAJ |
| description | Background: The therapeutic targeting of PD-1/PD-L1 has shown clinical efficacy in treating metastatic breast cancer. We investigated the clinical significance of measuring serum PD-L1 levels in African-American and Hispanic women with breast cancer. Methods: PD-L1 levels were measured with the ELISA method from the serum samples of 244 African-Americans and Hispanics with breast cancer and 155 women without cancers. The levels of INFα2 and TNFα were measured with a Luminex multiplex assay. The protein levels of pAkt and CD44/CD24 in tumor cells were tested with immunohistochemistry analysis. Cox regression was used to assess the predicting role of serum PD-L1 for disease-free survival (DFS). Results: PD-L1 levels were significantly elevated in breast cancer cases compared to non-cancer cases. The high PD-L1 levels were associated with HER2-positive and triple-negative breast cancer. PD-L1 level independently predicted DFS in both African-American and Hispanic women. The evaluated PD-L1 level was found to be associated with high IFNα2 and TNFα in breast cancer patients. Conclusions: PD-L1 serum levels can predict DFS in African American and Hispanic women with breast cancer. Furthermore, a high level of PD-L1 is more likely to be associated with tumor loss PTEN and the activation of Akt or with breast cancer cells expressing CD44high/CD24low. Further validation studies are needed to determine if PD-L1 could serve as a biomarker for patient selection for anti-PD-L1 therapy and assess treatment outcomes. |
| first_indexed | 2024-03-10T01:14:34Z |
| format | Article |
| id | doaj.art-d297726b595749c19ffd110a297e4aa2 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T01:14:34Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-d297726b595749c19ffd110a297e4aa22023-11-23T14:11:23ZengMDPI AGJournal of Clinical Medicine2077-03832022-01-0111228310.3390/jcm11020283Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic WomenYanyuan Wu0Pranabananda Dutta1Sheilah Clayton2Amaya McCloud3Jaydutt V. Vadgama4Division of Cancer Research and Training, Department of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USADivision of Cancer Research and Training, Department of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USADivision of Cancer Research and Training, Department of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USADivision of Cancer Research and Training, Department of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USADivision of Cancer Research and Training, Department of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USABackground: The therapeutic targeting of PD-1/PD-L1 has shown clinical efficacy in treating metastatic breast cancer. We investigated the clinical significance of measuring serum PD-L1 levels in African-American and Hispanic women with breast cancer. Methods: PD-L1 levels were measured with the ELISA method from the serum samples of 244 African-Americans and Hispanics with breast cancer and 155 women without cancers. The levels of INFα2 and TNFα were measured with a Luminex multiplex assay. The protein levels of pAkt and CD44/CD24 in tumor cells were tested with immunohistochemistry analysis. Cox regression was used to assess the predicting role of serum PD-L1 for disease-free survival (DFS). Results: PD-L1 levels were significantly elevated in breast cancer cases compared to non-cancer cases. The high PD-L1 levels were associated with HER2-positive and triple-negative breast cancer. PD-L1 level independently predicted DFS in both African-American and Hispanic women. The evaluated PD-L1 level was found to be associated with high IFNα2 and TNFα in breast cancer patients. Conclusions: PD-L1 serum levels can predict DFS in African American and Hispanic women with breast cancer. Furthermore, a high level of PD-L1 is more likely to be associated with tumor loss PTEN and the activation of Akt or with breast cancer cells expressing CD44high/CD24low. Further validation studies are needed to determine if PD-L1 could serve as a biomarker for patient selection for anti-PD-L1 therapy and assess treatment outcomes.https://www.mdpi.com/2077-0383/11/2/283PD-L1TNBCsurvivalCD44PTEN |
| spellingShingle | Yanyuan Wu Pranabananda Dutta Sheilah Clayton Amaya McCloud Jaydutt V. Vadgama Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women Journal of Clinical Medicine PD-L1 TNBC survival CD44 PTEN |
| title | Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women |
| title_full | Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women |
| title_fullStr | Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women |
| title_full_unstemmed | Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women |
| title_short | Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women |
| title_sort | elevated baseline serum pd l1 level may predict poor outcomes from breast cancer in african american and hispanic women |
| topic | PD-L1 TNBC survival CD44 PTEN |
| url | https://www.mdpi.com/2077-0383/11/2/283 |
| work_keys_str_mv | AT yanyuanwu elevatedbaselineserumpdl1levelmaypredictpooroutcomesfrombreastcancerinafricanamericanandhispanicwomen AT pranabanandadutta elevatedbaselineserumpdl1levelmaypredictpooroutcomesfrombreastcancerinafricanamericanandhispanicwomen AT sheilahclayton elevatedbaselineserumpdl1levelmaypredictpooroutcomesfrombreastcancerinafricanamericanandhispanicwomen AT amayamccloud elevatedbaselineserumpdl1levelmaypredictpooroutcomesfrombreastcancerinafricanamericanandhispanicwomen AT jayduttvvadgama elevatedbaselineserumpdl1levelmaypredictpooroutcomesfrombreastcancerinafricanamericanandhispanicwomen |